Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- New Health Ministry Panel to Compile Report on Clinical Research Regulations by Autumn
April 18, 2014
- Blue Letter on Xeplion Issued Following 21 Reported Deaths; Causal Relationship Remains Unclear
April 18, 2014
- Govt Deregulation Panel Tenders Prerequisites for Envisaged Mixed Care System
April 17, 2014
- MHLW to Mull Applying Mixed Care Scheme to Low Cost-Effective Drugs: Minister
April 17, 2014
- Govt Panel Members Pitch Yearly NHI Price Cut, 0.8 Trillion Yen Could’ve Been Pruned over 7 Years
April 17, 2014
- PAFSC’s First Committee to Review Canagliflozin, Japan’s 5th SGLT-2 Inhibitor
April 15, 2014
- Pharma Leaders Push Abe Govt to Permanently Introduce Key Premium, R&D Tax Credit
April 15, 2014
- MHLW Panel on Counterfeit Drugs Holds First Meeting
April 14, 2014
- MHLW Diovan Panel Finalizes Report following Fine-Tuning
April 14, 2014
- “Transparency Must Be Ensured” for Funding by Pharmas: Minister
April 14, 2014
- Number of High-Cost New Drugs to Be Reimbursed Under Fee-for-Service System: Chuikyo
April 14, 2014
- Japan NIH Will Have Research Topic-Based Units to Stem Sectionalism: Official
April 11, 2014
- Japanese NIH-Related Bills Clear Lower House
April 11, 2014
- 14-Day Prescription Limit to Be Ruled Out for Anti-HIV Drug Tivicay
April 11, 2014
- Official Says Health Ministry Will Notify Industry about Electronic Data Submissions around June
April 11, 2014
- Abe’s Govt, Pharma Leaders to Hold Public-Private Dialogue on April 14
April 10, 2014
- MHLW Says Additional Data Needed for OBLEAN Listing
April 10, 2014
- Chuikyo OKs Listing of 14 APIs including Japan’s First SGLT-2 Inhibitor
April 10, 2014
- PAFSC’s Committee Requires Face-to-Face Consultations for Sale of 25 OTC Drugs Including Allegra FX
April 10, 2014
- MHLW’s Study Committee on Clinical Research Systems to Hold 1st Meeting on April 17
April 10, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…